OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals has appointed Dr. Prakash Raman to its board of directors. Raman brings more than 20 years of experience in leadership and business development roles in the biopharma industry, most recently as CEO of InduPro Therapeutics and previously in senior positions at Ribon Therapeutics, Flagship Pioneering and Novartis. Olema is advancing palazestrant in two Phase-3 studies and developing the KAT6 inhibitor OP-3136; the stock currently trades at $14.14 with a market capitalization of about $1.27 billion. » More on de.investing.com

Olema Pharmaceuticals’ shares fell about 2.9% in after-hours trading following the announcement that Chief Operating and Financial Officer Shane Kovacs will leave on January 30, 2026. Kovacs will remain available in an advisory capacity until August 1, 2026. CEO Sean P. Bohen will temporarily assume the CFO duties while a search for a successor begins. Olema continues to advance its lead candidate palazestrant through late-stage clinical trials and to expand its breast cancer pipeline. » More on de.investing.com

Shane Kovacs will resign as Chief Operating and Financial Officer effective Jan. 30, 2026, and will advise Olema through Aug. 1, 2026. The company has launched a search for a new chief financial officer; until an appointment is made, Dr. Sean P. Bohen will temporarily assume the duties of principal financial officer. Olema, a biopharmaceutical company focused on targeted breast cancer therapies, is advancing palazestrant in two Phase‑3 studies and has a market capitalization of roughly $2 billion; the stock has recently rallied strongly. » More on de.investing.com